"name","description","instanceType","uuid:ID","id","label","text"
"OBJ1","Main objective","Objective","c7bc7736-ed0a-4ba0-b6cd-1266b250f457","Objective_1","","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."
"OBJ2","Safety","Objective","48f88b54-68b1-48af-a175-ce0fdb52e53f","Objective_2","","To document the safety profile of the xanomeline TTS."
"OBJ3","Behaviour","Objective","d096d1bf-9bd0-40cd-bf83-9cc07ebbb920","Objective_3","","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas."
"OBJ4","","Objective","1e59b63a-1483-4792-8195-43c8f41b2188","Objective_4","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5)."
"OBJ5","","Objective","adfdfd36-1c65-4c7c-83f1-e7490dfb2cee","Objective_5","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2)."
"OBJ6","","Objective","da056539-3c0c-4649-b9db-414a4fc44cfa","Objective_6","","To assess the treatment response as a function of Apo E genotype."
